We are live on ! Find out more
FC

Finepoint Capital Portfolio holdings

AUM $1.95B
1-Year Est. Return 45.61%
This Fund
S&P 500
This Quarter Est. Return
-2.31%
1 Year Est. Return
+45.61%
3 Year Est. Return
+24.83%
5 Year Est. Return
+26.66%
10 Year Est. Return
–
AUM
$309M
AUM Growth
+$5.25M
Cap. Flow
+$5.62M
Cap. Flow %
1.82%
Top 10 Hldgs %
59.65%
Holding
61
New
4
Increased
8
Reduced
7
Closed
17

Top Buys

Rank Stock Value
1
SRPT icon
Sarepta Therapeutics
SRPT
+$15.2M
2
CRNX icon
Crinetics Pharmaceuticals
CRNX
+$14.5M
3
RLAY icon
Relay Therapeutics
RLAY
+$13.7M
4
SWTX
SpringWorks Therapeutics
SWTX
+$8.25M
5
APLS
Apellis Pharmaceuticals
APLS
+$3.65M

Top Sells

Rank Stock Value
1
RCUS icon
Arcus Biosciences
RCUS
+$16.9M
2
ARGX icon
argenx
ARGX
+$10.2M
3
ISEE
IVERIC bio, Inc. Common Stock
ISEE
+$5.98M
4
ASTL icon
Algoma Steel
ASTL
+$3.26M
5
FOLD
Amicus Therapeutics
FOLD
+$2.93M

Sector Composition

Rank Sector Weight
1 Healthcare 89.87%
2 Materials 6.6%
Name Market Value Portfolio Weight Shares or Principal Change
in Stake 		Capital Flow
HCNEW
26
DELISTED
Jaws Hurricane Acquisition Corp. Warrant
HCNEW
$62K 0.02%
387,249
– –
SNRHW
27
DELISTED
Senior Connect Acquisition Corp. I Warrant
SNRHW
$61K 0.02%
1,014,000
– –
CCV.WS
28
DELISTED
Churchill Capital Corp V Warrants, each exercisable for one share of Class A common stock at an exercise price of $11.50 per share
CCV.WS
$49K 0.02%
612,000
– –
CNDA.WS
29
DELISTED
Concord Acquisition Corp II Warrants, each whole warrant exercisable for one share of Class A Common Stock at an exercise price of $11.50
CNDA.WS
$47K 0.02%
408,333
– –
CDAQW
30
DELISTED
Compass Digital Acquisition Corp. Warrant
CDAQW
$37K 0.01%
459,906
– –
IVCPW
31
DELISTED
Swiftmerge Acquisition Corp. Warrants
IVCPW
$36K 0.01%
490,000
– –
CLDI.WS
32
DELISTED
Calidi Biotherapeutics, Inc. Redeemable Warrants, each whole warrant exercisable for 1/10th of a share of Common Stock at an exercise price of $115.00
CLDI.WS
$33K 0.01%
655,200
– –
TWCBW
33
DELISTED
Bilander Acquisition Corp. Warrant
TWCBW
$33K 0.01%
183,749
– –
CCVI.WS
34
DELISTED
Churchill Capital Corp VI Warrants, each exercisable for one share of Class A common stock at an exercise price of $11.50 per share
CCVI.WS
$32K 0.01%
540,000
– –
BACA.WS
35
DELISTED
Berenson Acquisition Corp. I Warrants, each whole warrant exercisable for one share of class A common stock at an exercise price of $11.50
BACA.WS
$31K 0.01%
862,499
– –
GATEW
36
DELISTED
Marblegate Acquisition Corp. Warrant
GATEW
$29K 0.01%
735,000
– –
AFTR.WS
37
DELISTED
AfterNext HealthTech Acquisition Corp Warrants
AFTR.WS
$28K 0.01%
366,666
– –
CVIIW
38
DELISTED
Churchill Capital Corp VII Warrants
CVIIW
$27K 0.01%
548,000
– –
ROSS.WS
39
DELISTED
Ross Acquisition Corp II Warrants, each whole warrant exercisable for one Class A ordinary share at an exercise price of $11.50 per share
ROSS.WS
$22K 0.01%
439,666
– –
HPLTW
40
DELISTED
Home Plate Acquisition Corporation Warrant
HPLTW
$7K ﹤0.01%
690,000
– –
SKYAW
41
DELISTED
Skydeck Acquisition Corp. Warrants
SKYAW
$7K ﹤0.01%
361,756
– –
LVRAW
42
DELISTED
Levere Holdings Corp. Warrant
LVRAW
$4K ﹤0.01%
274,999
– –
CPARW
43
DELISTED
Catalyst Partners Acquisition Corp. Warrant
CPARW
$1K ﹤0.01%
336,666
– –
ARGX icon
44
argenx
ARGX
$53.8B
– –
-28,770
Closed -$10.2M
RCUS icon
45
Arcus Biosciences
RCUS
$3.44B
– –
-646,586
Closed -$16.9M
GTPAW
46
DELISTED
Gores Technology Partners, Inc. Warrant
GTPAW
– –
-201,000
Closed -$38K
GTPBW
47
DELISTED
Gores Technology Partners II, Inc. Warrant
GTPBW
– –
-450,691
Closed -$72K
STRY.WS
48
DELISTED
Starry Group Holdings, Inc. Warrants, each whole warrant exercisable to purchase 1.2415 shares of Class A common stock at an exercise price of $11.50 per 1.2415 shares of Class A common stock
STRY.WS
– –
-669,000
Closed -$87K
FCAX.WS
49
DELISTED
Fortress Capital Acquisition Corp. Warrants, each whole warrant exercisable for one Class A ordinary share at an exercise price of $11.50 per share
FCAX.WS
– –
-392,000
Closed -$31K
KAHC.WS
50
DELISTED
KKR Acquisition Holdings I Corp. Redeemable Warrants, each whole Warrant exercisable for one share of Class A Common Stock, each at an exercise price of $11.50 per share
KAHC.WS
– –
-588,547
Closed -$71K
1
2
3

Similar funds

NIM
Needham Investment Management New York $1.96B AUM 101.23% 1-Year Est. Return
WPC
Waters Parkerson & Co New Orleans, Louisiana $1.95B AUM 15.9% 1-Year Est. Return
SGAM
Smith Group Asset Management Dallas, Texas $1.96B AUM 43.61% 1-Year Est. Return
HA
Heartland Advisors Milwaukee, Wisconsin $1.96B AUM 28.26% 1-Year Est. Return
BC
Blackhill Capital Morristown, New Jersey $1.94B AUM 18.09% 1-Year Est. Return
FFH
Fairfax Financial Holdings Toronto, Ontario, Canada $1.94B AUM 27.76% 1-Year Est. Return
NFG
Nations Financial Group Cedar Rapids, Iowa $1.94B AUM 25.76% 1-Year Est. Return
MWA
Midland Wealth Advisors Effingham, Illinois $1.94B AUM 14.31% 1-Year Est. Return

Finepoint Capital's Q4 2022 Portfolio in Review

As of Q4 2022, Finepoint Capital held 61 positions worth $309M, up 1.7% from $304M the previous quarter. Its ten largest holdings account for 60% of the portfolio.

Finepoint Capital's Q4 2022 filing shows 4 new, 8 increased, 7 reduced and 17 closed positions. Its largest new stake was Sarepta Therapeutics: 131,457 shares worth $17M. The largest sale was Arcus Biosciences, an estimated $16.9M.

By sector, the portfolio is most concentrated in Healthcare at 90% of assets, up from 87% a quarter earlier, followed by Materials.

  • Finepoint Capital's largest Q4 2022 buy was Sarepta Therapeutics: 131,457 shares worth $17M.
  • Finepoint Capital added most to SpringWorks Therapeutics in Q4 2022, an estimated $8.25M increase.
  • Finepoint Capital's biggest Q4 2022 reduction was IVERIC bio, Inc. Common Stock, cutting an estimated $5.98M.
  • Finepoint Capital fully exited Arcus Biosciences in Q4 2022, selling an estimated $16.9M.
  • Finepoint Capital's ten largest holdings make up 60% of its $309M portfolio in Q4 2022.
  • Finepoint Capital opened 4 new positions and closed 17 in Q4 2022.
  • Finepoint Capital's portfolio value rose 1.7% quarter-over-quarter to $309M.

Based on Finepoint Capital's 13F filing for Q4 2022, filed 13 Feb 2023.